How effective is Myfembree (Ryeqo) in treating uterine fibroids

Myfembree’s experimental data

The LIBERTY randomized clinical trial showed that oral myfembree (Ryeqo) combination therapy (40 mg repaglinide, 1 mg estradiol, and 0.5 mg norethindrone acetate once daily) significantly improved uterine fibroid-related symptoms and conditions, including heavy menstrual bleeding, pain, and anemia, and was well tolerated.

Research purpose

This study aimed to evaluate the impact of combination therapy on symptom burden and health-related quality of life in women with uterine fibroids.

research design

LIBERTY 1 and LIBERTY 2 were two replicate, multinational, double-blind, 24-week, randomized, placebo-controlled Phase 3 studies in premenopausal women with uterine fibroid-related heavy menstrual bleeding (≥80 ml per cycle for 2 cycles or ≥160 ml in 1 cycle).

Test results

In both trials, 509 women were randomly assigned to receive the Robolith combination therapy or placebo (April 2017 to December 2018). Participants who received the myfembree (Ryeqo) combination therapy experienced statistically significant reductions from baseline to Week 24 in symptom severity (-33.5 vs -12.1; nominal P < .0001) and bleeding and pelvic discomfort subscales (-48.4 vs -17.4; nominal P < .0001) compared with participants who received placebo.

Overall, total health-related quality of life scores improved significantly from baseline to Week 24 in the myfembree combination group compared with the placebo group (+37.6 vs +13.1; nominal P < .0001). Responder analysis showed that more women treated with myfembree (Ryeqo) combination therapy reported clinically meaningful reductions in the bleeding and pelvic discomfort subscales and improvements in physical and social activities compared with women treated with placebo (nominal P < .0001).

Test conclusion

After 24 weeks of myfembree combination therapy, women with symptomatic uterine fibroids experienced significant improvements in health-related quality of life, with improvements on all subscales, including emotional well-being, physical and social activities, and sexual function. Additionally, women reported significant reductions in overall symptom burden and distress from major uterine fibroid-related symptoms.

The effects of myfembree(Ryeqo)

myfembree is a combination of relugolix, estradiol, and norethindrone acetate. Relugolix reduces the production of estrogen and other hormones by the ovaries; estradiol reduces the risk of bone loss; and norethindrone acetate is a synthetic progestin necessary for estrogen in women with a uterus. myfembree (Ryeqo) has been approved for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Myfembree(Ryeqo) drug purchase channels

myfembree (Ryeqo) is not yet available in China, and it is not available in domestic hospital pharmacies. Patients in need can go to areas where it is already available, but the distance is long, there is no guarantee, and the cost is high. Patients can also obtain it through domestic professional overseas medical service organizations (such as Medical Companion Travel), and the drugs can be mailed to their homes to ensure authenticity. However, the price of drugs is not fixed due to various factors. It is recommended to consult customer service staff for specific costs and acquisition procedures. Obtaining drugs is guaranteed.

Recommended related articles:

References

Stewart EA, Lukes AS, Venturella R, Li Y, Hunsche E, Wagman RB, Al-Hendy A. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2023 Mar;228(3):320.e1-320.e11. doi: 10.1016/j.ajog.2022.11.1278. Epub 2022 Nov 9. PMID: 36370871.